Columbia University Vagelos College of Physicians and Surgeons

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Retrieved on: 
Wednesday, June 29, 2022
Annual report, Patient, Securities Act of 1933, Securities Exchange Act of 1934, Columbia University Irving Medical Center, LM, Trial of the century, GLOBE, Columbia University, Columbia University Vagelos College of Physicians and Surgeons, Population, Blood, Company, MDSC, Brachytherapy, PSA, TAAS, Immune system, Form, TME, Prostate-specific antigen, Neoplasm, Regulatory T cell, Technology, Drug Quality and Security Act, Physician, SEC, Prostate cancer, Medicine, Immunotherapy, Tumor microenvironment, Safety, Listeria monocytogenes, MD, Forward-looking statement, Form 8-K, Pharmaceutical industry, Vaccine, Advaxis, Surgeon

MONMOUTH JUNCTION, N.J., June 29, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center. Karie Runcie, MD, assistant professor of medicine, and Mark N. Stein, MD, associate professor of medicine, in the division of hematology/oncology at Columbia University Vagelos College of Physicians and Surgeons, are the study’s principal and senior investigators, respectively.

Key Points: 
  • The preliminary clinical assessment of patients at the first dose level has shown that ADXS-504 monotherapy is safe and well tolerated.
  • Clinical and immunogenicity data, including PSA values, for patients in both cohorts will be presented at a future medical conference.
  • Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products.
  • The Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made.

Four New York City Cancer Centers Receive $1 Million SU2C Grant to Improve Lung Cancer Care in Underserved Minority Patients

Retrieved on: 
Monday, June 27, 2022
Department, Patient, SU2C, Lung cancer, Research, Oncology, Adoption, Health, Columbia University Vagelos College of Physicians and Surgeons, Smartphone, Mount Sinai, Awareness, NYU Langone Health, Stand Up to Cancer, Academic health science centre, Hematology, Health status of Asian Americans, Bristol Myers Squibb, Technology, Nursing, NYU, Icahn School of Medicine at Mount Sinai, Physician, Albert Einstein College of Medicine, Surgeon, Immunotherapy, New York University Grossman School of Medicine, MD, Department of Medicine – University of Pamplona, Pharmaceutical industry, Medical device, Medicine, NSCLC

The grant will establish the Lung Cancer Health Equity SU2C Catalyst Research Team.

Key Points: 
  • The grant will establish the Lung Cancer Health Equity SU2C Catalyst Research Team.
  • The grant is made possible by the support of Bristol Myers Squibb and is a part of SU2C's Health Equity Initiative .
  • Underserved minority patients with NSCLC treated with immunotherapy face numerous barriers to using technology to report adverse effects.
  • The researchers plan to enroll 500 patients in the catchment areas of the four academic medical centers in New York City.

n-Lorem Foundation Introduces First ‘Partner in Excellence’ to Support and Accelerate the Treatment of Nano-rare Patients

Retrieved on: 
Tuesday, June 14, 2022
Research, Hospitals, Genetics, Philanthropy, Biotechnology, Pharmaceutical, Health, Foundation, Other Philanthropy, Science, Life, Leadership, Pediatrics, Columbia University Irving Medical Center, Time, Program, Chung, Research, Department of Neurology, Xuanwu hospital, Partner, LinkedIn, CEO, RNA, Columbia University Vagelos College of Physicians and Surgeons, Disease, YouTube, Ionis Pharmaceuticals, Hope, Therapy, Physician, Columbia, Patient, DRS, DNA, ALS, Natural history, Columbia University, Twitter, Department, Efficiency, Lists of diseases, Surgeon, Eleanor, Instagram, Neurology, ASO, Pharmaceutical industry, Medicine, Facebook, Excellence

I am pleased to announce our first Partner in Excellence collaborators and to confirm our support in working closely with Drs.

Key Points: 
  • I am pleased to announce our first Partner in Excellence collaborators and to confirm our support in working closely with Drs.
  • n-Lorems Partner in Excellence program aligns research physicians, world-class institutions and n-Lorem with the common goal to provide the highest quality healthcare and treatment for nano-rare patients.
  • Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options.
  • To date, n-Lorem has assisted in the development and treatment of 14 nano-rare patients and received over 140 applications for treatment with more than 60 nano-rare patients approved.

Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team

Retrieved on: 
Thursday, May 26, 2022
Biotechnology, Pharmaceutical, Health, Senior, Chemistry, NEA, Inflammation, Pain, Investment, COO, Doctor of Philosophy, Mayo Clinic, CSO, Drug discovery, Leadership, Dub, MTORC1, Degenerative disease, Physiology, Clinical professor, Pfizer, Depression, Ubiquitin, Research, Neurodegeneration, Lists of diseases, CNS, TPS, Wyeth, Mark (given name), Columbia University Vagelos College of Physicians and Surgeons, Protein, Cancer, Pierre and Marie Curie University, Pharmaceutical industry, Pharmacology

Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer.

Key Points: 
  • Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer.
  • Dr. Saiah has co-authored more than 120 scientific publications, patents, reviews and presentations.
  • In addition, Stablix announced that Dr. Kevin Sprott, Ph.D., has been promoted to Chief Operating Officer from Senior Vice President, Drug Discovery.
  • The appointment of Eddine as CSO and Kevin as COO significantly expands our executive leadership team and makes a strong statement about our commitment to build a world-class innovative company, said Stablixs CEO Tony Kingsley.

College Hazing Can Lead to Personal Injury Lawsuits

Retrieved on: 
Thursday, May 12, 2022
Survivor, Hazing, Columbia University Vagelos College of Physicians and Surgeons, Cardiac arrest, Multimedia, Parent, Columbia Missourian, Haze, Child, Injury, Family, University, Insurance, Online shopping

ATLANTA , May 12, 2022 /PRNewswire/ -- An increase in college-related injuries and fraternity hazing practices has led to an increase in lawsuits in the last decade. In many of the injury cases that involve hazing, liability is typically placed on the fraternity and its individual members, rather than the university or college where the hazing took place.

Key Points: 
  • In many of the injury cases that involve hazing, liability is typically placed on the fraternity and its individual members, rather than the university or college where the hazing took place.
  • Numerous parties have made large payments to injured victims as a result of lawsuits against fraternities, including chapter members, colleges, national chapters and fraternity members responsible for the hazing.
  • This is just one example of the numerous hazing lawsuits that happen every year, and it could happen to anyone.
  • Lead attorney Matthew Stoddard says, "Sending your child off to college should be an exciting experience, but unfortunately, it can lead to life-threatening situations.

RubiconMD Welcomes Behavioral Health Medical Director, Ludwing Salamanca, MD, PhD

Retrieved on: 
Wednesday, May 11, 2022
Health, General Health, Epidemiology, CME, Columbia University, PCP, Â, Mount Sinai, Patient, Doctor of Philosophy, Columbia University Vagelos College of Physicians and Surgeons, New York State Psychiatric Institute, Physician, Surgeon, Public health, Medical director, Research, EConsult, Medicine, Pharmaceutical industry, Medical device, MD

RubiconMD, the market leader for virtual specialty eConsults announced today that Ludwing Salamanca, MD, PhD will be joining the organization as their first-ever Behavioral Health Medical Director.

Key Points: 
  • RubiconMD, the market leader for virtual specialty eConsults announced today that Ludwing Salamanca, MD, PhD will be joining the organization as their first-ever Behavioral Health Medical Director.
  • He has been a consultant for the RubiconMD platform for the last three years and leads quarterly behavioral health care CME webinars.
  • He will develop a long-term strategy to continually grow the behavioral health team, recruiting top psychiatrists from around the US.
  • It has been amazing to witness the transformation that RubiconMD has made from eConsults to supporting longitudinal behavioral health through collaborative care.

NewYork-Presbyterian Announces $50 Million Gift from the Jane and Daniel Och Family Foundation to Expand World-Class Och Spine Care Across the New York Metro Area

Retrieved on: 
Wednesday, May 11, 2022
Weill Cornell Medicine, Neck pain, Human, Columbia University Irving Medical Center, Hospital, NewYork-Presbyterian Lawrence Hospital, Orthopedic surgery, Spine, CEO, Spiral, Scoliosis, Neurology, YouTube, Twitter, Telehealth, Columbia University, Patient, Therapy, Program, Physician, Center, Surgeon, U.S. News & World Report Best Hospitals Rankings, Research, Association of Academic Physiatrists, Greater New York, Ochs, Instagram, Jane, Weill Cornell Medical Center, Board of directors, Columbia University Vagelos College of Physicians and Surgeons, Nursing, Growth, Multimedia, Board, Department, Travel, TAVR, New York State Department of Health, Trustee, Health, News, PAP, Bookbinding, Medicine, NewYork-Presbyterian Hospital, Facebook

The transformative gift will increase access to Och Spine care by establishing more Och Spine facilities across the New York Metro area, including in underserved communities.

Key Points: 
  • The transformative gift will increase access to Och Spine care by establishing more Och Spine facilities across the New York Metro area, including in underserved communities.
  • This is the second major gift from Jane and Dan Och, who donated $25 million in 2017 to transform spine care at NewYork-Presbyterian, helping to build Och Spine Hospital as the premier spine program in the world.
  • "We look forward to expanding access to our Och Spine services across the Greater New York area."
  • "At Och Spine, our operative and non-operative clinicians work together to deliver personalized, comprehensive care to each patient for their particular spine issue."

n-Lorem Foundation and Columbia University Establish Silence ALS Initiative

Retrieved on: 
Tuesday, May 3, 2022
University, Education, Other Health, Health, Philanthropy, General Health, Other Philanthropy, Research, Fund Raising, Foundation, Science, People, Hope, Motor neuron, Mutation, Department, Brain, YouTube, Instagram, Twitter, Eleanor, RNA, Glass, Columbia University, Diagnosis, Patient, Target, Columbia University Vagelos College of Physicians and Surgeons, Partnership, Neurology, Clinical trial, Amyotrophy, Physician, Spinal cord, Therapy, DNA, Surgeon, Leadership, Natural history, Efficiency, LinkedIn, ASO, California Healthcare Institute, Disease, Ionis Pharmaceuticals, Life, Genetics, Amyotrophic lateral sclerosis, CEO, Research, Biology, ALS, Department of Neurology, Xuanwu hospital, Ecosystem, Pharmaceutical industry, Dentistry, Medicine, Silence, Facebook

Silence ALS targets those nano-rare ALS patients who have a genetic mutation found in only 1 to 30 affected individuals worldwide.

Key Points: 
  • Silence ALS targets those nano-rare ALS patients who have a genetic mutation found in only 1 to 30 affected individuals worldwide.
  • The Silence ALS initiative will create the most efficient process to connect the diagnosis and treatment of patients with some of the extremely rare mutations that cause ALS.
  • Watch : n-Lorem Foundation: Creating a Better Future for Nano-Rare, One Patient at a Time
    Silence ALS is a newly formed initiative between Columbia University and n-Lorem with Target ALS as a founding donor.
  • Silence ALS plans to establish an infrastructure to enable ASO discovery and development for carriers of nano-rare ALS gene mutations.

Renovations Begin on NewYork-Presbyterian Iona School of Health Sciences

Retrieved on: 
Friday, April 29, 2022
Communication studies, Columbia University Vagelos College of Physicians and Surgeons, The Princeton Review, Program, Catholic (term), BA, Outline of health sciences, Social work, College, Weill Cornell Medicine, Physician, Marriage, Learning, MA, Iona College, Mental health counselor, Student, Business administration, Master of Arts, Occupational therapy, U.S. News & World Report, Christian Brothers, Business, MBA, BS, News, Surgeon, Medicine, NewYork-Presbyterian Hospital, White Plains Road, Nursing, Science, Disorder

BRONXVILLE, N.Y., April 29, 2022 /PRNewswire-PRWeb/ -- Renovations are now underway on the future home of the NewYork-Presbyterian Iona School of Health Sciences in Bronxville, N.Y. Offering a cutting-edge education in state-of-the-art new facilities, classes on Iona's second campus are expected to commence Spring 2023.

Key Points: 
  • Iona College is building this premier new school of health sciences in collaboration with NewYork-Presbyterian to develop the next generation of world-class health care professionals.
  • Degrees are currently being offered through the NewYork-Presbyterian Iona School of Health Sciences in Nursing (BS); Social Work (BS); Speech-Language Pathology & Audiology (BA); Occupational Therapy (MS); Communication Sciences & Disorders (MA); Marriage & Family Therapy (MS); and Mental Health Counseling (MA).
  • In July 2021, Iona College and NewYork-Presbyterian announced the establishment of the NewYork-Presbyterian Iona School of Health Sciences, to be principally located on the College's new campus at 171 White Plains Road, Bronxville, N.Y.
  • Supported by a $20 million gift from NewYork-Presbyterian, the NewYork-Presbyterian Iona School of Health Sciences is expected to offer a new vision for collaborative health care education, modern workforce development, and community care.

MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research

Retrieved on: 
Thursday, April 21, 2022
Code, Nasdaq, Herbert Irving Comprehensive Cancer Center, Tokyo Stock Exchange, NASDAQ, Mothers (Tokyo Stock Exchange), Columbia University Irving Medical Center, MD, Metastasis, MIF, Exosome, Associate, GLOBE, Hematology-Oncology and Stem Cell Transplantation Research Center, Doctor of Philosophy, Columbia University, Cell biology, Melanoma, UM, Hepatocyte, Macrophage migration inhibitory factor, Pathology, Columbia University Vagelos College of Physicians and Surgeons, Uveal melanoma, Physician, Cytokine, Molecular Cancer Research, Uvea, Research, Pharmaceutical industry, Vaccine, Medicine, Surgeon

The publication describes a preclinical study which characterized the proteomic content of uveal melanoma exosomes and identified the presence of markers with metastatic properties.

Key Points: 
  • The publication describes a preclinical study which characterized the proteomic content of uveal melanoma exosomes and identified the presence of markers with metastatic properties.
  • Key take-aways in the publication include:
    Uveal melanoma exosomes (UM-exo) induce activation of cell signaling pathways and the release of cytokines and growth factors from hepatocytes.
  • MIF blockade inhibited UM cell migration in co-cultures with exosome-stimulated hepatocytes and prevented the development of metastases in vivo.
  • This study provided the first in vivo evidence that MIF inhibition may serve as a novel adjuvant drug therapy to prevent metastasis in uveal melanoma.